Trial · NCT07888933
Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay
NCT07888933, Phase 2, Not yet recruiting, University of Sao Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay. Trials, record NCT07888933. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888933
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay
- NCT number
- NCT07888933
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 106 participants, estimated
- Lead sponsor
- University of Sao Paulo
- Conditions
- Suicidal Ideation, Suicidal Behavior
- Interventions
- Esketamine, Midazolam (Intravenous)
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Psychiatric Hospital Discharge | From the first study infusion until discharge from the index psychiatric hospitalization, assessed up to 6 months. | Time, in days, from the first study infusion to discharge from the index psychiatric hospitalization. Hospital discharge will be considered the event of interest. Participants who do not experience the event during the observation period will be censored at the last date for which outcome information is available. Time to discharge will be compared between participants randomized to intravenous esketamine and participants randomized to active placebo. |
| Secondary | Remission of Suicidal Ideation at 72 Hours | 72 hours after the first study infusion | Proportion of participants achieving complete remission of suicidal ideation, defined as a Scale for Suicide Ideation (SSI) score ≤3. |
| Secondary | Change in Suicidal Ideation Severity | Baseline through Week 12 | Change in clinician-rated and self-rated Scale for Suicide Ideation (SSI) scores from baseline across treatment and follow-up assessments. Higher scores indicate greater severity of suicidal ideation. |
| Secondary | Suicidal Ideation and Behavior During Follow-up | Baseline through Week 12 | Change in suicidal ideation and occurrence of suicidal behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). |
| Secondary | Suicide Attempts During Follow-up | From the first study infusion through Week 12 | Number and proportion of participants experiencing at least one suicide attempt during clinical follow-up. |
| Secondary | Change in Depressive Symptoms Assessed by PHQ-9 | Baseline through Week 12 | Change in Patient Health Questionnaire-9 total score from baseline. Higher scores indicate greater severity of depressive symptoms. |
| Secondary | Change in Depressive Symptoms Assessed by QIDS-SR | Baseline through Week 12 | Change in Quick Inventory of Depressive Symptomatology-Self-Report total score from baseline. |
| Secondary | Change in Clinician-Rated Depressive Symptoms | Baseline through Week 12 | Change in Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) total score from baseline. |
| Secondary | Change in Psychological Pain | Baseline through Week 12 | Change in Psychological Pain Visual Analog Scale (PPP-VAS) score from baseline. |
| Secondary | Change in Hopelessness | Baseline through Week 12 | Change in Beck Hopelessness Scale (BHS) total score from baseline. Higher scores indicate greater hopelessness. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888933
GET https://conductscience.org/api/trials/v1/NCT07888933/registered?page=2